Skip to content

More federal states against higher THC limit in road traffic

  • News

After Bavaria, Lower Saxony, and North Rhine-Westphalia, Hamburg and Schleswig-Holstein have also spoken out against raising the THC limit in road traffic. "The top priority must always be traffic safety," the Schleswig-Holstein Ministry of Economic Affairs and Transport told "Redaktionsnetzwerk Deutschland". "The state government of Schleswig-Holstein has clearly committed to Vision Zero. An increase in the limit would counteract this [...] More federal states against higher THC limit in road traffic

Prof. Dr. Hilmar Dörge ist Vorsitzender der leitenden Herzchirurgen in Deutschland

Prof. Dr. Hilmar Dörge, Direktor der Klinik für Herz- und Thoraxchirurgie am Klinikum Fulda, wurde zum Vorsitzenden der Arbeitsgemeinschaft Leitender Herzchirurgen (ALHK) gewählt. Die Wahl fand im Rahmen des jährlichen Kongresses der ALHK in Berlin statt. Die „Arbeitsgemeinschaft Leitende Herzchirurgische Krankenhausärzte e. V.“ ist ein Zusammenschluss von Herzchirurgen, die als Chefarzt oder Chefärztin an einem […] Prof. Dr. Hilmar Dörge ist Vorsitzender der leitenden Herzchirurgen in Deutschland

Gedeon Richter: Cariprazine could become best-selling atypical antipsychotic drug

  • News

Cariprazine, an original antipsychotic drug developed by Hungarian pharmaceutical company Gedeon Richter Plc. is available in 64 countries and has become a multiple blockbuster in the US, with sales of nearly $3 billion. It is a unique achievement that a Hungarian drug candidate – discovered and developed locally – has been granted FDA and EU approvals, and the company already has several further molecules in its pipeline. "Thousands of psychiatrists arrived to Budapest for the European Congress of Psychiatry, and perhaps even they are unaware of how important role Hungarian researchers have played in this field worldwide. We have nearly 1200 researchers, making us the largest innovation base in the whole region. The fact that cariprazine has been among the TOP 100 drugs by sales for several years now is an outstanding achievement comparable to winning an Olympic medal," Gábor Orbán, CEO of Richter said… 

MEDSIR: Two Translational Studies Focused on Biomarkers at AACR 2024

  • News

MEDSIR, a leading company dedicated to the strategic design of independent clinical research, participated in the Annual Meeting of the American Association for Cancer Research, a premier event that brings together scientists, clinicians, industry professionals, advocates, and other stakeholders in the field of cancer research, presenting the results of two sub-studies focused on biomarkers: transFal, focused on patients with HR+/HER2- advanced breast cancer and METSGain, centered on patients with early breast cancer. Both studies underscore the importance of utilizing biomarkers. Their early detection has been shown to increase patient survival rates by aiding in selecting the most appropriate treatment for patients. In the context of personalized medicine, biomarkers are also important for tailoring treatments for individual patients based on their unique biological characteristics, allowing for more precise and effective medical interventions. These findings represent significant strides in understanding and leveraging… 

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the approval of the CE Mark for the VENTANA® HER2 (4B5) Rabbit Monoclonal Primary Antibody RxDx* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® (trastuzumab deruxtecan) may be considered as a targeted treatment. The test, which is branded PATHWAY in the United States, received US Food and Drug Administration (FDA) approval in October 2022. ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca. HER2 is a receptor protein that helps cancer cells grow quickly. To determine a patient’s HER2 status, pathologists evaluate, or score, the level of HER2 protein expressed in breast cancer tissue samples. If a patient’s tumour expresses high levels of HER2, the patient is identified as HER2-positive and may be considered for HER2-targeted treatment. However,… 

Börsengänge Schweiz/International: IPO-Fantasie wird im 1. Quartal zur Realität

Es hatte sich schon abgezeichnet, dass das Eis auch an den europäischen Primärmärkten brechen würde. Der US-IPO-Markt hatte sich schon 2023 belebt und auch im ersten Quartal 2024 das Niveau gehalten. Zwei der vier Mega-IPOs mit Emissionserlösen über 1 Mrd. USD kommen nun aus Europa. Der andere Star ist Indien mit 27% aller globalen IPOs, […] Börsengänge Schweiz/International: IPO-Fantasie wird im 1. Quartal zur Realität

Mortality figures in March significantly below previous years' levels

The number of deaths in Germany in March 2024 was significantly lower than in previous years. In total, 83,263 people died, according to a projection published on Tuesday by the Federal Statistical Office (Destatis), which is eight percent less than the average for the years 2020 to 2023. In February 2024, the number of deaths was still above the average for previous years […] Mortality figures in March significantly below previous years' levels

Künstliche Intelligenz beschert Microsoft Rekord-Kundenzuwachs

Microsoft kann aufgrund seiner Investitionen in Künstliche Intelligenz (KI) einen Rekord-Kundenzuwachs verzeichnen. Das teilte der Konzern dem „Handelsblatt“ (Mittwochausgabe) mit. In den USA setzten demnach 85 Prozent der Konzerne im Fortune-100-Index auf Microsofts KI-Angebote. Weltweit seien es über 53.000 Organisationen. „Fast alle großen Unternehmen testen generative KI. Wir haben noch nie eine so schnelle Akzeptanz […] Künstliche Intelligenz beschert Microsoft Rekord-Kundenzuwachs

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

– Aberrant TRIM7 expression identified as a key driver of immune checkpoint blockade (ICB) acquired resistance; inhibition of TRIM7 with small molecule inhibitors may prevent or reverse acquired resistance to PD-1/L1 blockade – Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

FOSTER CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Notable Labs, Ltd. (Nasdaq: NTBL) (“Notable” or the “Company”), a clinical-stage precision oncology company developing a new class of cancer therapies identified by its Predictive Precision Medicine Platform (PPMP), today presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR 2024) being held in San Diego, CA (Poster abstract 5178). Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024